HIV resistance study seeks answers on dolutegravir failure
NCT ID NCT06762054
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 6,600 people with HIV who have developed resistance to the drug dolutegravir. Researchers want to see if continuing the same medication with extra counseling can still suppress the virus. The goal is to learn more about how resistance develops and how to manage it effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dolutegravir (DTG)
What this could lead to
If successful, this study could provide evidence on whether continuing DTG-based therapy with enhanced counseling is effective for managing resistance, potentially simplifying treatment guidelines.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all populations, and resistance patterns could limit viral suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bomu Hospital
NOT_YET_RECRUITINGMombasa, Kenya
Contact
-
Butha-Buthe District Hospital
RECRUITINGButha-Buthe, Lesotho
Contact
-
CS Machava II
NOT_YET_RECRUITINGMaputo, Mozambique
Contact
-
CS Ndlavela
NOT_YET_RECRUITINGMaputo, Mozambique
Contact
-
CS Ponta Gea
NOT_YET_RECRUITINGBeira, Sofala, Mozambique
Contact
-
Jaramogi Oginga Odinga Teaching and Referral Hospital
RECRUITINGKisumu, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kenyatta National Hospital
RECRUITINGNairobi, 00100, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MUHAS Clinical Trial Unit
NOT_YET_RECRUITINGDar es Salaam, Tanzania
Contact
-
Mokhotlong District Hospital
RECRUITINGMokhotlong, Lesotho
Contact